We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
-7.9%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$1.39B
AUM Growth
-$202M
Cap. Flow
+$27.4M
Cap. Flow %
1.97%
Top 10 Hldgs %
51.89%
Holding
98
New
17
Increased
22
Reduced
21
Closed
23

Top Buys

Rank Stock Value
1
BBNX
Beta Bionics
BBNX
+$63.3M
2
NVCR icon
NovoCure
NVCR
+$63.2M
3
PRAX icon
Praxis Precision Medicines
PRAX
+$56M
4
STAA icon
STAAR Surgical
STAA
+$51.4M
5
HOLX
Hologic
HOLX
+$20M

Top Sells

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$29.3M
2
AXGN icon
Axogen
AXGN
+$27.2M
3
AZN icon
AstraZeneca
AZN
+$26.8M
4
QDEL icon
QuidelOrtho
QDEL
+$24.4M
5
SNDX icon
Syndax Pharmaceuticals
SNDX
+$23.6M

Sector Composition

Rank Sector Weight
1 Healthcare 91.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVL
26
DELISTED
Nuvalent
NUVL
$15.2M 1.09%
214,357
+110,000
+105% +$8.6M
ANIP icon
27
ANI Pharmaceuticals
ANIP
$1.88B
$15M 1.08%
224,684
+19,390
+9% +$1.16M
FOCL
28
EDAP TMS S.A.
FOCL
$231M
$14.3M 1.03%
7,309,254
– –
IKT icon
29
Inhibikase Therapeutics
IKT
$380M
$13.9M 1%
6,325,000
– –
EOLS icon
30
Evolus
EOLS
$488M
$13M 0.93%
1,079,158
+382,000
+55% +$5M
PHVS icon
31
Pharvaris
PHVS
$2.4B
$12.8M 0.92%
814,652
– –
SNY icon
32
Sanofi
SNY
$104B
$12.5M 0.9%
+226,218
New +$12.2M
CCCC icon
33
C4 Therapeutics
CCCC
$402M
$11.2M 0.8%
6,978,942
– –
SLNO
34
DELISTED
Soleno Therapeutics
SLNO
$10.7M 0.77%
+150,000
New +$7.3M
KNSA icon
35
Kiniksa Pharmaceuticals
KNSA
$5.97B
$10.4M 0.75%
+469,500
New +$9.66M
ACLX
36
DELISTED
Arcellx
ACLX
$10M 0.72%
153,031
+32,000
+26% +$2.17M
SNDX icon
37
Syndax Pharmaceuticals
SNDX
$1.77B
$10M 0.72%
816,610
-1,675,390
-67% -$23.6M
OFIX icon
38
Orthofix Medical
OFIX
$428M
$9.82M 0.71%
601,925
-84,449
-12% -$1.48M
TNDM icon
39
Tandem Diabetes Care
TNDM
$1.29B
$9.5M 0.68%
+496,039
New +$14.5M
SRRK icon
40
Scholar Rock
SRRK
$6.32B
$9.16M 0.66%
285,000
+117,457
+70% +$4.52M
ASND icon
41
Ascendis Pharma A/S
ASND
$16.4B
$8.77M 0.63%
56,300
-87,700
-61% -$12.5M
PTGX icon
42
Protagonist Therapeutics
PTGX
$9.41B
$8.17M 0.59%
169,000
-106,000
-39% -$4.44M
IMUX icon
43
Immunic
IMUX
$197M
$7.95M 0.57%
729,301
– –
CGON icon
44
CG Oncology
CGON
$6.59B
$7.43M 0.54%
303,585
-25,000
-8% -$703K
TEVA icon
45
Teva Pharmaceuticals
TEVA
$40.6B
$6.92M 0.5%
450,500
-1,642,500
-78% -$29.3M
THTX
46
DELISTED
Theratechnologies
THTX
$6.72M 0.48%
4,801,376
– –
JSPR icon
47
Jasper Therapeutics
JSPR
$21.8M
$6.43M 0.46%
1,494,420
– –
INSP icon
48
Inspire Medical Systems
INSP
$1.7B
$6.21M 0.45%
+39,000
New +$7.06M
VSTM icon
49
Verastem
VSTM
$519M
$5.64M 0.41%
935,909
-1,248,117
-57% -$7.63M
AKRO
50
DELISTED
Akero Therapeutics
AKRO
$4.74M 0.34%
+117,000
New +$4.96M
1
2
3 4

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return
QT
Quantbot Technologies New York $2.44B AUM 17.13% 1-Year Est. Return

Soleus Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Soleus Capital Management held 98 positions worth $1.39B, down 13% from $1.59B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Soleus Capital Management's Q1 2025 filing shows 17 new, 22 increased, 21 reduced and 23 closed positions. Its largest new stake was Beta Bionics: 3,395,341 shares worth $41.6M. The largest sale was Teva Pharmaceuticals, an estimated $29.3M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 83% a quarter earlier.

  • Soleus Capital Management's largest Q1 2025 buy was Beta Bionics: 3,395,341 shares worth $41.6M.
  • Soleus Capital Management added most to NovoCure in Q1 2025, an estimated $63.2M increase.
  • Soleus Capital Management's biggest Q1 2025 reduction was Teva Pharmaceuticals, cutting an estimated $29.3M.
  • Soleus Capital Management fully exited AstraZeneca in Q1 2025, selling an estimated $26.8M.
  • Soleus Capital Management's ten largest holdings make up 52% of its $1.39B portfolio in Q1 2025.
  • Soleus Capital Management opened 17 new positions and closed 23 in Q1 2025.
  • Soleus Capital Management's portfolio value fell 13% quarter-over-quarter to $1.39B.

Based on Soleus Capital Management's 13F filing for Q1 2025, filed 15 May 2025.